Molecular diagnosis | Treatment | Distribution |
---|---|---|
ALK+ | Alectinib | 95% |
Crizotinib | 5% | |
EFGR+ | Erlotinib | 3,3% |
Gefitinib | 6,7% | |
Afatinib | 11.7% | |
Osimertinib | 76.3% | |
Dacomitinib | 2% | |
ROS1+ | Crizotinib | 95% (40%a) |
Clinical trials | 5% | |
Entrectinib | 0% (55%a) | |
WT | ||
TPS ≥50% | Pembrolizumab monotherapy | 90% |
Cisp+pmtrx | 5% | |
Clinical trials | 5% | |
TPS < 50% | Cisp+pmtrx | 25% |
Carb+paclitx+beva | 5% | |
Cisp+pmtrx+pembrolizumab | 60% | |
Carb+ paclitx +beva+atezolizumab | 10% |